Compare Paychex, Inc. (PAYX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Sanofi SA — how do they compare? Paychex, Inc. trades at $114.91 (market cap $40.85B), while Sanofi SA trades at $42.96 (market cap $103.41B). The key difference: Sanofi SA is far larger — about 2.5× Paychex, Inc.'s market cap, and Sanofi SA pays the higher dividend (5.65%). Which is the better fit depends on your goals.
| PAYX | SNY | |
|---|---|---|
Market Cap | $40.85B | $103.41B |
Sector | Industrials | Health |
52-Week High | $135.46 | $52.34 |
52-Week Low | $85.57 | $41.33 |
Enterprise Value | $44.33B | $123.44B |
Dividend Yield | 4.15% | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $116.93, down 3.93% in the last session. The stock shows strong profitability with a net income margin of 27.03% and ROE of 44.77%. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.32 surpassing the $1.31 estimate. Technical indicators are mixed, with a bearish moving average signal but RSI suggesting potential oversold conditions. The company continues to expand its AI-driven WISE platform, enhancing service efficiency for small businesses.
The outlook for PAYX is cautiously optimistic, supported by robust cash flow and strategic AI integration. However, risks include elevated valuation multiples and competitive pressures in the HR solutions space. Analyst consensus is a 'Hold' with a $120 price target, indicating limited near-term upside from current levels amid balanced growth and risk factors.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
